Short acting beta2 agonists are primarily used for what purpose?

Short-acting beta2 agonists (SABAs) are primarily used for acute asthma relief due to their rapid onset of action. These medications work by relaxing the muscles around the airways, leading to bronchodilation, which helps alleviate symptoms such as wheezing, shortness of breath, and chest tightness during an asthma attack or exacerbation.

Because of their quick action, SABAs are often referred to as "rescue" inhalers, suitable for immediate symptom relief rather than long-term management. They do not provide lasting control of asthma symptoms or address underlying inflammation, which is better managed with other classes of medications such as inhaled corticosteroids. Their primary purpose is to be used as needed during acute episodes or when experiencing acute symptoms, thus making them critical in an asthma action plan for patients.

In contrast, other options like long-term asthma control and preventive therapy typically involve different categories of medications, such as inhaled corticosteroids or leukotriene modifiers, which address underlying inflammation and help in maintaining overall asthma control. Anti-inflammatory effects are also associated more closely with controllers rather than rescue medications, highlighting why SABAs are specifically aligned with acute symptoms rather than long-term management.